Evidence map›Paper›PMID 31413092›Full record

ArticleHaematologica2020

PIEZO1 activation delays erythroid differentiation of normal and hereditary xerocytosis-derived human progenitor cells.

Alexis Caulier, Nicolas Jankovsky, Yohann Demont, Hakim Ouled-Haddou, Julien Demagny, Corinne Guitton, Lavinia Merlusca, Delphine Lebon, Pascal Vong, Aurélien Aubry and 10 more

Open access · goldAbstract read
In one paragraph

Article in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 57 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Role of the mechanotransductor PIEZO1 in megakaryocyte differentiation.Journal of cellular and molecular medicine · 2024
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 1 country.

Alexis CaulierEA4666 HEMATIM, Université Picardie Jules Verne, Amiens.
Nicolas JankovskyEA4666 HEMATIM, Université Picardie Jules Verne, Amiens.
Yohann DemontUnité de Thérapie Cellulaire, CHU Amiens, Amiens.
Hakim Ouled-HaddouEA4666 HEMATIM, Université Picardie Jules Verne, Amiens.
Julien DemagnyService d'Hématologie Biologique, CHU Amiens.
Corinne GuittonService de Pédiatrie Générale, CHU Bicêtre, AP-HP, Le Kremlin-Bicêtre.
Lavinia MerluscaService des Maladies du Sang, CHU Amiens, Amiens.
Delphine LebonEA4666 HEMATIM, Université Picardie Jules Verne, Amiens.
Pascal VongEA4666 HEMATIM, Université Picardie Jules Verne, Amiens.
Aurélien AubryEA4666 HEMATIM, Université Picardie Jules Verne, Amiens.
Agnès LaharyLaboratoire d'Hématologie, CHU Rouen, Rouen.
Christian RoseService d'Oncologie et d'Hématologie, Hôpital Saint Vincent de Paul, Lille.
Sandrine GréaumeEtablissement Français du Sang (EFS) de Normandie, Bois-Guillaume.
Emilie CardonEA4666 HEMATIM, Université Picardie Jules Verne, Amiens.
Jessica PlatonEA4666 HEMATIM, Université Picardie Jules Verne, Amiens.
Halima Ouadid-AhidouchEA4667 Laboratoire de Physiologie Cellulaire et Moléculaire, Université Picardie Jules Verne, Amiens.
Jacques RochetteEA4666 HEMATIM, Université Picardie Jules Verne, Amiens.
Jean-Pierre MarolleauEA4666 HEMATIM, Université Picardie Jules Verne, Amiens.
Véronique PicardLaboratoire d'Hématologie, AP-HP, Le Kremlin-Bicêtre, France.
Loïc GarçonEA4666 HEMATIM, Université Picardie Jules Verne, Amiens garcon.loic@chu-amiens.fr.
Centre Hospitalier Universitaire Amiens-Picardie · FRHématopoïèse et immunologie · FRAssistance Publique – Hôpitaux de Paris · FRBicêtre Hospital · FRCentre Hospitalier Universitaire de Rouen · FRÉtablissement Français du Sang · FRHôpital Saint-Vincent-de-Paul · FRLaboratoire de physiologie cellulaire et moléculaire · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hereditary xerocytosis is a dominantly inherited red cell membrane disorder caused in most cases by gain-of-function mutations in PIEZO1, encoding a mechanosensitive ion channel that translates a mechanic stimulus into calcium influx. We found that PIEZO1 was expressed early in erythroid progenitor cells, and investigated whether it could be involved in erythropoiesis, besides having a role in the homeostasis of mature red cell hydration. In UT7 cells, chemical PIEZO1 activation using YODA1 repressed glycophorin A expression by 75%. This effect was PIEZO1-dependent since it was reverted using specific short hairpin-RNA knockdown. The effect of PIEZO1 activation was confirmed in human primary progenitor cells, maintaining cells at an immature stage for longer and modifying the transcriptional balance in favor of genes associated with early erythropoiesis, as shown by a high

Indexed as

Anemia, Hemolytic, CongenitalIon ChannelsCell DifferentiationErythropoiesisHumansHydrops FetalisStem CellsIon ChannelsPIEZO1 protein, human

Identifiers

PMID31413092
PMCPMC7049340
OpenAlexW2969208081

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.